U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 09:10:53 GMT 2023
Edited
by admin
on Sat Dec 16 09:10:53 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
5D6PWO0333
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLANEZUMAB
INN   WHO-DD  
INN  
Official Name English
solanezumab [INN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN .BETA.-AMYLOID) (HUMAN-MOUSE MONOCLONAL LY2062430 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL LY2062430 LIGHT CHAIN, DIMER
Common Name English
LY2062430
Code English
SOLANEZUMAB [JAN]
Common Name English
LY-2062430
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN .BETA.-AMYLOID PEPTIDE) (HUMANIZED MONOCLONAL LY2062430 HEAVY CHAIN, DISULFIDE WITH HUMANIZED MONOCLONAL LY2062430 LIGHT CHAIN, DIMER)
Common Name English
Solanezumab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN .BETA.-AMYLOID PEPTIDE) (HUMANIZED MONOCLONAL LY2062430 HEAVY CHAIN, DISULPHIDE WITH HUMANIZED MONOCLONAL LY2062430 LIGHT CHAIN, DIMER)
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN .BETA.-AMYLOID) (HUMAN-MOUSE MONOCLONAL LY2062430 HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL LY2062430 LIGHT CHAIN, DIMER
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
Code System Code Type Description
EVMPD
SUB37126
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL1743072
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
DRUG BANK
DB11756
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
CAS
955085-14-0
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
FDA UNII
5D6PWO0333
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
INN
9097
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
NCI_THESAURUS
C88585
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
WIKIPEDIA
SOLANEZUMAB
Created by admin on Sat Dec 16 09:10:53 GMT 2023 , Edited by admin on Sat Dec 16 09:10:53 GMT 2023
PRIMARY
From To
1_22 1_96
1_139 1_195
1_256 1_316
1_362 1_420
2_22 2_96
2_139 2_195
2_256 2_316
2_362 2_420
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
1_215 3_219
2_215 4_219
1_221 2_221
1_224 2_224
Glycosylation Link Type Site
N 1_292
N 2_292
Related Record Type Details
HUMAN .BETA.-AMYLOID PEPTIDE (1-42)
TARGET->LIGAND
Designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.
HUMAN .BETA.-AMYLOID PEPTIDE (1-40)
TARGET->LIGAND
Designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.
Related Record Type Details
SOLANEZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966